ACA
NVAX icon

Avoro Capital Advisors’s Novavax NVAX Stock Holding History

Avoro Capital Advisors’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-15,000
Closed -$1.78M – 40
2014
Q4 		$1.78M Buy
+15,000
New +$1.57M 1.21% 22

Other funds holding NVAX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Avoro Capital Advisors's NVAX Position: Q1 2015 in Review

Avoro Capital Advisors sold out of Novavax (NVAX) in Q1 2015, closing a stake of 15,000 shares — an estimated $1.78M sold.

Avoro Capital Advisors first reported a position in NVAX in Q4 2014 and held it in 1 quarter. The position peaked at $1.78M in Q4 2014. 167 funds tracked by Wall St. Rank hold NVAX as of Q1 2015.

  • Avoro Capital Advisors reported no remaining Novavax position as of Q1 2015 after selling out during the quarter.
  • Avoro Capital Advisors sold 15,000 Novavax shares in Q1 2015, an estimated $1.78M.
  • Avoro Capital Advisors first reported a position in Novavax in Q4 2014 and held it in 1 quarter.
  • Avoro Capital Advisors's Novavax position peaked at $1.78M in Q4 2014.
  • 167 funds tracked by Wall St. Rank held Novavax as of Q1 2015.

Based on Avoro Capital Advisors's 13F filing for Q1 2015, filed 15 May 2015.